Vorinostat (CAS 149647-78-9): Comprehensive Technical Guide
Table of Contents
1. Chemical & Pharmacological Profile
| Parameter | Value |
|---|---|
| CAS Number | 149647-78-9 |
| Molecular Formula | C14H20N2O3 |
| Molecular Weight | 264.32 g/mol |
| Appearance | White crystalline solid |
| Melting Point | 159-168°C |
| Solubility | 1,167 mg/L in water (25°C), soluble in DMSO/ethanol |
| Storage | -20°C in dry conditions |
2. Mechanism of Action
As a pan-HDAC inhibitor, Vorinostat demonstrates:
- ID50 = 10 nM (HDAC1)
- ID50 = 20 nM (HDAC3)
Key biological effects include:
- Histone hyperacetylation induction
- p21WAF1 upregulation
- Cell cycle arrest at G1 phase
- Apoptosis activation via caspase pathways
3. Therapeutic Applications
FDA-approved for:
- Cutaneous T-cell lymphoma (CTCL) treatment
- Refractory cases after ≥2 systemic therapies
Investigational uses:
- HPV-related neoplasms (inhibition of HPV-18 DNA amplification)
- Combination therapies with DNA methyltransferase inhibitors
4. Clinical Case Studies
Case 1: Advanced CTCL Management
A 58-year-old patient with stage III CTCL showed 30% tumor burden reduction after 12 weeks of Vorinostat monotherapy (400 mg/day).
Case 2: Combination Therapy
Phase II trial demonstrated 45% overall response rate when combined with 5-azacytidine in myelodysplastic syndromes.
5. Supplier Information
| Supplier | Purity | Packaging |
|---|---|---|
| MedChemExpress | ≥99% | 50 mg to 1 g |
| TargetMol | 99.93% | 1 mg to 1 g |
| CRS Bio | Pharma Grade | Bulk CMO |
For technical specifications or bulk orders:
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。